Athenex Revenue and Competitors
Estimated Revenue & Valuation
- Athenex's estimated annual revenue is currently $117M per year.
- Athenex received $100.0M in venture funding in July 2018.
- Athenex's estimated revenue per employee is $928,968
- Athenex's total funding is $312.1M.
- Athenex's current valuation is $120.3M. (January 2022)
Employee Data
- Athenex has 126 Employees.
- Athenex grew their employee count by -10% last year.
Athenex's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO & Chairman | Reveal Email/Phone |
2 | Chief Accounting Officer (CAO) | Reveal Email/Phone |
3 | Director Quality | Reveal Email/Phone |
4 | Director Supply Chain Planning | Reveal Email/Phone |
5 | Director Information Technology | Reveal Email/Phone |
6 | Regional Director Finance | Reveal Email/Phone |
7 | Manager Legal Affairs | Reveal Email/Phone |
8 | Senior Quality Assurance Manager | Reveal Email/Phone |
9 | Sales and Operational Planning | Reveal Email/Phone |
10 | Senior Supply Chain Analyst | Reveal Email/Phone |
Athenex Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $12.3M | 61 | 7% | N/A | N/A |
#2 | $354.3M | 461 | -2% | $567.1M | N/A |
#3 | $377.1M | 1876 | -1% | N/A | N/A |
#4 | $7.8M | 39 | 8% | N/A | N/A |
#5 | $5.4M | 27 | 0% | N/A | N/A |
#6 | $45M | 224 | 6% | N/A | N/A |
#7 | $6.8M | 34 | -82% | N/A | N/A |
#8 | $9.2M | 46 | 12% | N/A | N/A |
#9 | N/A | 694 | 46% | N/A | N/A |
#10 | $15.5M | 77 | 5% | N/A | N/A |
What Is Athenex?
Athenex is a global specialty oncology pharmaceutical company focused on the development and commercialization of next generation therapies for cancer diseases and supportive therapies. The company is dedicated to delivering innovative drugs that can have a life-changing impact on cancer patients. Our business includes medical technology innovation centers and a unique manufacturing supply chain across both China and North America. Through the connected innovation and manufacturing supply chain presence, we can identify, develop and deliver proprietary medical technology across continents and multiple regulatory environments.
keywords:Biotechnology,Healthcare,Pharmaceuticals
$312.1M
Total Funding
126
Number of Employees
$117M
Revenue (est)
-10%
Employee Growth %
$120.3M
Valuation
N/A
Accelerator
Athenex News
The market has been down on Athenex Inc (ATNX) stock recently. ATNX gets a Bearish score from InvestorsObserver Stock Sentiment Indicator.
According to Zacks, Athenex, Inc. is a clinical stage biopharmaceutical company. It engaged in the discovery and development of drugs for the...
Buffalo biopharmaceutical company Athenex has had its share of struggles over the last year, and here's another one: The publicly traded...
BUFFALO, N.Y., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that Johnson Lau, CEO and Boar ...
Athenex Provides Third Quarter 2021 Corporate and Financial Update Held FDA Type A Meeting for oral paclitaxel in metastatic breast cancer Klisyri® launched in Europe ANCHOR Phase 1 interim results accepted for poster presentation at 2021 ASH 3Q product sales were $27.0M, up 9% year-over-yea ...
Other Companies in Buffalo
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $22.7M | 126 | 6% | N/A |
#2 | $31.6M | 126 | 9% | N/A |
#3 | $22.9M | 127 | 0% | N/A |
#4 | $35.1M | 130 | 8% | N/A |
#5 | $7.5M | 130 | 8% | N/A |
Athenex Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2018-01-23 | $Undisclosed | Undisclosed | Deutsche Bank Securities | Article |
| 2018-01-26 | $75.4M | Undisclosed | Deutsche Bank Securities | Article |
| 2018-07-03 | $100.0M | Undisclosed | Perceptive Advisors | Article |